We are live on ! Find out more
BC

Broadwood Capital Portfolio holdings

AUM $1.42B
1-Year Est. Return 34.72%
This Fund
S&P 500
This Quarter Est. Return
+21.75%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$867M
AUM Growth
+$147M
Cap. Flow
+$2.12M
Cap. Flow %
0.24%
Top 10 Hldgs %
100%
Holding
7
New
Increased
1
Reduced
Closed

Top Buys

Rank Stock Value
1
IMDX
Insight Molecular Diagnostics
IMDX
+$2.12M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 51.27%
2 Consumer Staples 34.29%
3 Industrials 6.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
STAA icon
1
STAAR Surgical
STAA
$1.21B
$381M 43.96%
10,840,630
MNST icon
2
Monster Beverage
MNST
$94.3B
$297M 34.29%
9,358,616
IWM icon
3
iShares Russell 2000 ETF
IWM
$79.8B
$69.6M 8.02%
420,000
AXON
4
Axon Enterprise
AXON
$42.5B
$55.7M 6.42%
760,062
LCTX icon
5
Lineage Cell Therapeutics
LCTX
$269M
$30.3M 3.49%
34,005,379
IMDX
6
Insight Molecular Diagnostics
IMDX
$150M
$27.6M 3.18%
613,737
+58,824
+11% +$2.12M
SER icon
7
Serina Therapeutics
SER
$30M
$5.46M 0.63%
85,219

Similar funds

Broadwood Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Broadwood Capital held 7 positions worth $867M, up 20% from $720M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2019: portfolio turnover was 0%. Broadwood Capital opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 47% a quarter earlier, followed by Consumer Staples and Industrials.

  • Broadwood Capital added most to Insight Molecular Diagnostics in Q4 2019, an estimated $2.12M increase.
  • Broadwood Capital's ten largest holdings make up 100% of its $867M portfolio in Q4 2019.
  • Broadwood Capital opened 0 new positions and closed 0 in Q4 2019.
  • Broadwood Capital's portfolio value rose 20% quarter-over-quarter to $867M.

Based on Broadwood Capital's 13F filing for Q4 2019, filed 14 Feb 2020.